Results from Phase I Study of CB-839 in Combination with Everolimus or Cabozantinib in Patients with Renal Cell Carcinoma to be Presented at the 2018 American Society of Clinical Oncology Genitourinary Cancer Symposium

World News: . []

SOUTH SAN FRANCISCO Calif Feb 05 2018 GLOBE NEWSWIRE -- Calithera Biosciences Inc NasdaqCALA a clinical stage biotechnology company focused on the development of novel cancer therapeutics announced today that clinical data from its l ead pro...

More news and information about Calithera Biosciences, Inc.

Published By:

Globe Newswire: 22:04 GMT Monday 5th February 2018

Published: .

Search for other references to "results" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us